TITLE:
BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis

CONDITION:
Juvenile Rheumatoid Arthritis

INTERVENTION:
Abatacept

SUMMARY:

      The primary purpose of the clinical research study is to assess the safety of treating
      children and juvenile subjects with BMS-188667 (Abatacept). In addition, the study will
      assess the effectiveness of BMS-188667 in reducing disease activity of Juvenile Rheumatoid
      Arthritis (JRA) or Juvenile Idiopathic Arthritis (JIA) as measured by the time to occurrence
      of disease flare.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 6 Years to 17 Years
Criteria:

        Inclusion Criteria:

          -  Diagnosis of Juvenile Rheumatoid Arthritis or Juvenile Idiopathic Arthritis;

          -  Current active arthritis;

          -  Failed treatment with at least one disease modifying anti-rheumatic drug (DMARD);

          -  Subjects must discontinue use of any DMARD other than methotrexate prior to the first
             dose of study medication

        Exclusion Criteria:

          -  Presence of infection or history of frequent acute or chronic infections;

          -  Joint replacement surgery required during the study or history of surgery on more
             than 5 joints;

          -  Live vaccines within 3 months of the first dose of study medication;

          -  Unresolved serious bacterial infection or chronic bacterial infection;

          -  Subjects who currently have intermittent fever due to JRA/JIA, rheumatoid rash,
             hepato-splenomegaly, pleuritis, pericarditis, or macrophage activation syndrome.
      
